Red blood cell alloimmunization in Iran: A Comprehensive review of the literature

Maryam Sadat Hosseini, Leila Jafari, Reza Shiri Heris, Ahmad Gharehbaghian

Abstract:

BACKGROUND: Alloimmunization is an immune response against foreign antigens which introduced into the body through transfusion, pregnancy, or transplantation. This phenomenon is a big challenge in patients, which require regular transfusions. In the current study, we tried to have a comprehensive review on the status of alloimmunization in Iran. For this purpose, we searched for papers investigating alloimmunization in transfusion-dependent patients and also in patients with no regular transfusions who are candidate for surgery or who need blood.

METHODS: We searched PubMed, Google Scholar, SID, and MAGIRAN databases using the following keywords: "blood transfusion," "alloimmunization," "alloantibodies," "irregular antibodies," "red cell antibodies," and "Iran." No limitation for the date of publication and language of the papers was defined. All the identified records were then screened for the relevance and duplication.

RESULTS: A total of 22 papers were included in this study. All of the studies were conducted from 1999 to 2016 and providing alloimmunization data from different cities all over of Iran. In general, the results showed that the most prevalent alloantibodies are anti-Kell (anti-K antigen) and anti-Rh system, mainly anti-E, anti-D, anti-C, and anti-c.

CONCLUSION: Anti-Kell and anti-Rh antibodies are the most prevalent antibodies responsible for alloimmunization in Iranian population.

Keywords:
Alloantibody, alloimmunization, Iran, transfusion

Introduction

Since the first published report on human-to-human blood transfusion by James Blundell,[1] blood transfusion has become a relatively simple and life-saving part of daily medical practice. Allogeneic blood transfusion is a form of temporary transplantation. This procedure introduces a multitude of foreign antigens into the recipient, and thereby can stimulate the immune system. The incidence of transfusion-induced alloimmunization is debated and ranges from 1% to 3% in single-transfused individuals to 30% in multititransfused patients (e.g., sickle cell disease, thalassemia, and myelodysplasia).[3] The most commonly involved antigens are classified in the following categories: (1) red blood cell (RBC)-specific antigens; (2) granulocyte-specific antigens; (3) platelet-specific antigens (human platelet antigens); and human leukocyte antigens.[3,4]

With the improvement of health-care systems and medical technologies, there has been an increase in the number of chronic patients and also in major surgeries which require a higher number of blood transfusions. Thus, the frequency of RBC alloantibodies is increasing. The development of blood cell antibodies (alloantibodies and/or autoantibodies)
remains a significant challenge in transfusion therapy which limits the provision of compatible blood products for future transfusions. In the current study, we tried to have a comprehensive review on the status of red cell alloimmunization in Iranian population.

**Methods**

**Search strategy**

For this review study, we tried to collect all the related studies on alloimmunization against RBCs in Iranian patient population who underwent elective surgery or multitransfused patients. We searched PubMed, Google Scholar, SID, and MAGIRAN databases using the following keywords: “blood transfusion,” “alloimmunization,” “alloantibodies,” “irregular antibodies,” “red cell antibodies” and “Iran.” No limitation for the date of publication was defined and studies in either Persian or English languages were included.

All the identified records were then screened for the relevance of title and content. In the next step, duplicate papers which seem to have an overlap in their studied subjects were excluded. Figure 1 illustrates a schematic view of the search strategy.

**Data extraction**

We extracted the year of publication, number of included subjects, region of the study, proportion of patients with alloantibody/autoantibody, and type of the most commonly detected alloantibodies with their related frequencies.

**Results**

**Search results**

In the initial search, we identified a total of 31 papers. All 31 papers were assessed through abstracts and 7 papers were removed because of duplication or because they seem to have an overlap in the studied subjects. We also removed two papers because of the incomplete data. Finally, a total of 22 papers were included in this study, of which 10 papers were in Persian and 12 in English.

**Extracted data**

All of the studies were conducted from 1999 to 2016 and providing alloimmunization data from different cities/provinces all over of Iran. Most of the studies were conducted on patients with transfusion-dependent β-thalassemia (either with intermediate or major disease). The data of these studies are summarized in Table 1. In three out of 22 papers, patients without regular transfusions who were candidate for surgery or need blood underwent the assessment for antibody screening. Table 2 demonstrates an overview of these three studies.

**Discussion**

In most blood transfusion services, phenotyping and pretransfusion compatibilization of the most immunogenic antigens are normally applied to patients with chronic diseases. However, the risk of alloantibody development still remains a big challenge, particularly in developing countries where high costs of pretransfusion phenotyping do not allow it to be a part of routine transfusion procedure.

Alloimmunization is more highlighted in cases with regular transfusions, including patients with chronic anemia such as β-thalassemia major (or intermediate) and sickle cell disease, patients who underwent bone marrow transplantation, patients under heavy chemotherapeutic regimens, and lots of other conditions.

The blood transfusion services aim to provide a high-quality facility with no to minimum risk to the recipients. When humans are involved in any critical steps in the process of transfusion, errors are inevitable. Crossmatch is a critical step in pretransfusion testing which may be affected by a wide range of clerical and technical errors, such as mislabeled or partially labeled tubes, misinterpretation of hemolysis in serum grouping as negative, and blood group discrepancy due to inadequate washing of cells. A prospective study was performed at a blood center (18-month duration) to determine errors reported in the crossmatch laboratory. This study shows the importance of blood sample collection process and pretransfusion testing in preventing errors during transfusion. Furthermore, alloimmunization can occur because many alloantibodies may not be detected, as no further transfusions are required or because the titer of antibodies decrease over time and reaches a nondetectable level.
Table 1: Studies which assessed red cell immunization among Iranian patients with transfusion-dependent β-thalassemia

| Authors (references) | Year of publication | Number of patients | Region of study* | Incidence of immunization, n (%) | Prevalence of alloantibodies (%) |
|----------------------|---------------------|--------------------|-----------------|----------------------------------|---------------------------------|
| Davari and Soltanpour[6] | 2016 | 49 | Zanjan | 16.32 (allo-Ab) | Anti-K (60) Anti-E (10) Anti-c (10) Anti-Leb (10) |
| Younesi et al.[6] | 2016 | 240 | Tehran | 37.1 | Anti-K (46.7) Anti-E (18.1) Anti-D (11.4) Anti-C (6) Anti-c (4) Anti-Cw (3) Anti-Fyb (3) Anti-Lua (3) Anti-s (2) Anti-e (1) |
| Vaziri et al.[7] | 2015 | 100 | Yazd | 4 (allo-Ab) | Anti K (75) Anti-C, Anti-D (25) |
| Keikhaei et al.[8] | 2013 | 133 | Ahvaz | 18.7 (allo-Ab) 12.7 (auto-Ab) | Rh subgroups system (55) Kell system (33) |
| Mirzaeian et al.[9] | 2013 | 385 | Zahedan | 17.9 (allo-Ab) 5.5 (auto-Ab) | Undetermined (3.1) Anti-E (2.6) Anti-C (1.6) Anti-Lua (1.6) Anti-c (1.3) Anti-Cw (1.3) Anti-K (1) |
| Tahannejad-Asadi et al.[10] | 2013 | 70 | Ahvaz | 55 (allo-Ab) | Anti-K (4.3) Anti-E (2.2) Anti-D (2.2) |
| Kosaryan et al.[11] | 2012 | 218 | Sari | 40.4 (allo-Ab) | Anti- C, Cw, Lea (40) |
| Azarkeivan et al.[12] | 2011 | 835 | Multicenter (Tehran, Ghazvin, Karaj) | 12.1 (allo-Ab) 1 (auto-Ab) | Anti-Kell (33.7) Anti-D (10.9) Anti-E (9.9) |
| Obeidi et al.[13] | 2011 | 90 | Bushehr | 10 (allo-Ab) | Anti-K (18) Anti-Kell or Anti-Rh (81.6) Other (18.3) |
| Ansari et al.[14] | 2009 | 458 | Tehran (Ali asghar hospital) | 11.8 (allo) | Anti-D (88.8) Anti-C (33.3) Anti-E (11.1) |
| Sadeghian et al.[15] | 2009 | 313 | Mash' had | 2.87 (allo-Ab) | Anti-D (88.8) Anti-C (33.3) Anti-E (11.1) |
| Shamsian et al.[16] | 2008 | 121 | Tehran (Mofid children's hospital) | 7.4 (allo-Ab) | Anti-K (1.6) Anti-D (1.6) |
| Karimi et al.[17] | 2007 | 711 | Shiraz | 5.34 (allo-Ab) | Anti-K (19) Anti-D (6) Anti-E (4) |
| Kiani et al.[18] | 2006 | 65 | Lorestan | 1.53 | Anti-E (100)*** |
| Eshghi[19] | 2003 | 163 | Zahedan | 0 | Anti-K (27.5) Anti-N (12.5) Anti-Cw (5) Anti-s (5) Anti-Fyb (5) |
| Rahgozar et al.[20] | 2003 | 52 | Isfahan | 76.9 | Anti-K (27.5) Anti-N (12.5) Anti-Cw (5) Anti-s (5) Anti-Fyb (5) |

*Vaziri et al.[7] 2015: 100 Yazd 4 (allo-Ab)

Contd...
This phenomenon may also result from inappropriate methods of antibody detection. Anyway, it is an inevitable outcome of transfusion since the compatibility of all the transfused antigens is impossible.

Most of the studies on alloimmunization in Iranian patients included subjects with β-thalassemia (either intermediate or major). According to these studies, most of the detected alloantibodies are anti-Kell (anti-K antigen) and anti-Rh system antibodies mainly anti-E, anti-D, anti-C, and anti-c [Table 1]. We also found three studies which conducted on patients without regular transfusions who were candidate for elective surgery. These studies included a higher number of patients and provided more general data of Iranian population. Based on these studies, the most common cause of alloimmunization in males is transfusion and in females is pregnancy. All three papers introduced anti-K, anti-E, and anti-C/anti-c as the most common detected antibodies [Table 2]. The results of these studies are in agreement with the data obtained from thalassemic patients.

The development of anti-D antibody as one of the most common alloantibodies shows that we have still problems in blood group typing because D antigen is one of the main antigens which should be matched between donor and recipient, especially for young female recipients. This problem may reflect clerical and technical errors made

| Table 1: Contd... |
|-------------------|
| **Authors (references)** | **Year of publication** | **Number of patients** | **Region of study*** | **Incidence of immunization, n (%)** | **Prevalence of alloantibodies (%)** |
| Farsinejad and Poorfathollah[21] | 2003 | 300 | Kerman | 9 (allo-Ab) | Anti-Rh (47.7) Anti-MNS (9.1) Anti-kidd (6.8) |
| Ahmadi[22] | 2001 | 142 | Kermanshah | 9.2 | Anti-LuA (61.5) Anti-P1 (24.1) Anti-C (7.7) Anti-N (7.7) |
| Kaviani et al. | 1999 | 100 | Tehran and West Azerbaijan | 10 | Not mentioned** |

*Patients studied in each region may be native or not. *This study also included 24 Afghan patients. **The authors introduced Anti-Rh and Anti-Kell systems as the most common antibodies, but the exact incidence was not mentioned. ***Only one patient (1.53) was detected to have alloantibody which was against E antigen. Ab = Antibody

| Table 2: Studies which assessed red cell alloimmunization among Iranian patients without regular transfusions |
|--------------------------|
| **Authors (references)** | **Year of publication** | **Subjects** | **Number of patients** | **Region of study*** | **Incidence of alloimmunization, n (%)** | **Prevalence of alloantibodies (%)** |
| Gharehbaghian et al.[23] | 2014 | - | 1420 | Ardebil | 0.92 | Anti-K (30) Anti-E (15) Anti-c (15) |
| Khademi et al.[24] | 2013 | - | 3092 | Tehran | 0.9 | Anti-K (23.53) Anti-E (20.59) Anti-c (17.56) |
| Ghorbani Ali-Abadi et al.[25] | 2013 | - | 3487 | Shiraz | 0.8 | Anti-K (23) Anti-E (15) Anti-C (11) |

*Patients studied in each region may be native or not

before testing. This phenomenon may also result from inappropriate methods of antibody detection. Anyway, it is an inevitable outcome of transfusion since the compatibility of all the transfused antigens is impossible.

Most of the studies on alloimmunization in Iranian patients included subjects with β-thalassemia (either intermediate or major). According to these studies, most of the detected alloantibodies are anti-Kell (anti-K antigen) and anti-Rh system antibodies mainly anti-E, anti-D, anti-C, and anti-c [Table 1]. We also found three studies which conducted on patients without regular transfusions who were candidate for elective surgery. These studies included a higher number of patients and provided more general data of Iranian population. Based on these studies, the most common cause of alloimmunization in males is transfusion and in females is pregnancy. All three papers introduced anti-K, anti-E, and anti-C/anti-c as the most common detected antibodies [Table 2]. The results of these studies are in agreement with the data obtained from thalassemic patients.

The development of anti-D antibody as one of the most common alloantibodies shows that we have still problems in blood group typing because D antigen is one of the main antigens which should be matched between donor and recipient, especially for young female recipients. This problem may reflect clerical and technical errors made by the staff and also inappropriate or incomplete quality control of the reagents and equipment. Human errors may affect all the steps in a transfusion procedure; including prescription and request, patient sampling, pretransfusion testing, and finally the collection of the component from the blood refrigerator and administration to the patient. According to the literature, such errors considered as the main cause of transfusion reactions.

Our study with gathering the majority of studies on Iranian population from all over the country may provide an overview on the status of alloimmunization in Iran including the total incidence and the prevalence of responsible antibodies. Our review may also provide a better view for the future studies which in turn may lead to better management of the problem.

**Financial support and sponsorship**
Nil.

**Conflicts of interest**
There are no conflicts of interest.

**References**
1. Blundell J. Experiments on the transfusion of blood by the syringe. Med Chir Trans 1818;9:56-92.
2. Thakral B, Saluja K, Sharma RR, Marwaha N. Red cell
alloimmunization in a transfused patient population: A study from a tertiary care hospital in North India. Hematology 2008;13:313-8.

3. Gamit S, Shah P, Iyer R. Role of red blood cells (RBCs) alloimmunization in multiple transfusions. Southeast Asian J Case Rep Rev 2015;4:1137-52.

4. Brouk H, Bertrand G, Zitouni S, Djenouve A, Martageix C, Griffi F, et al. HPA antibodies in Algerian multitransfused patients: Prevalence and involvement in platelet refractoriness. Transfus Apher Sci 2015;52:295-9.

5. Davari K, Soltanpour MS. Study of alloimmunization and autoimmunization in Iranian β-thalassemia major patients. Asian J Transfus Sci 2016;10:89-92.

6. Younesi MR, Louni Aligoudarzi S, Bigdeli R, Lashgari M, Mazaheri H, Asgarg Y, et al. Alloimmunization against platelets, granulocytes and erythrocytes in multi-transfused patients in Iranian population. Transfus Apher Sci 2016;55:205-11.

7. Vaziri M, JavadzadehShahshahani H, Moghadam M, Taghvae N. Prevalence and specificities of red cell alloantibodies in transfusion-dependent beta thalassemia patients in Yazd. Iran J Ped Hematol Oncol 2015;5:93-9.

8. Keikhaei B, Hirad Far A, Abolghasemi H, Mousakhan H, Ghanavat M, Moghadam M, et al. Red blood cell alloimmunization in patients with thalassemia major and intermediate in Southwest Iran. Iran J Blood Cancer 2013;6:41-6.

9. Mirzaeian A, Tammadon G, Naderi M, Hosseinpour M, Sargolzaie N, Dorgalaleh A. Prevalence of alloimmunization against RBC antigens in thalassemia major patients in South East of Iran. J Blood Disord Transf 2016;4:92.

10. Tahannejad-Asadi Z, Elahi A, Mohseni A, Talebi M, Khosravi M, et al. Screening and identifying of erythrocyte alloantibodies in patients with thalassemia major in Kerman. J Ped Hematol Oncol 2015;5:93-9.

11. Farsinejad A, Poorfathollah Aa. Evaluation of immune antibodies against red cells in thalassemic patients in Kerman Province. Modares J Med Sci 2002;5:93-9.

12. Ahmadi D. Frequency of minor blood group alloantibodies in beta-thalassemia major blood recipients in Kermanshah (1999). Journal Of Kermanshah University Of Medical Sciences (Behbood) 2001;5:50-5.

13. Gharehbaghian A, Ghezelbash B, Aghazade S, Hojjati MT. Evaluation of alloimmunization rate and necessity of blood type and screening test among patients candidate for elective surgery. Int J Hematol Oncol Stem Cell Res 2014;8:1-4.

14. Bloch D, Tawfik H, Habib H, El-Kadri M, El Sahib M. Frequency & specificity of RBC alloantibodies in patients due for surgery in Iran. Indian J Med Res 2013;138:252-6.

15. Ghorbani Ali-Abadi E, Tavassoli A, Gharehbaghian A, Kasraian L, Khadem R, Taleie A. Evaluation of frequency and specificity of RBC alloantibodies in Namazi hospital patients in Shiraz, 2010. Sci J Iran Blood Transfus Organ 2013;10:239-45.

16. Santos FW, Magalhães SM, Mota RM, Pitombeira MH. Additional red blood cell alloantibodies after blood transfusions in a nonhematologic alloimmunized patient cohort: Is it time to take precautionary measures? Transfusion 2006;46:630-5.

17. Santos FW, Magalhães SM, Mota RM, Pitombeira MH. Additional red blood cell alloantibodies after blood transfusions in a nonhematologic alloimmunized patient cohort: Is it time to take precautionary measures? Transfusion 2006;46:630-5.

18. Santos FW, Magalhães SM, Mota RM, Pitombeira MH. Additional red blood cell alloantibodies after blood transfusions in a nonhematologic alloimmunized patient cohort: Is it time to take precautionary measures? Transfusion 2006;46:630-5.

19. Santos FW, Magalhães SM, Mota RM, Pitombeira MH. Additional red blood cell alloantibodies after blood transfusions in a nonhematologic alloimmunized patient cohort: Is it time to take precautionary measures? Transfusion 2006;46:630-5.

20. Santos FW, Magalhães SM, Mota RM, Pitombeira MH. Additional red blood cell alloantibodies after blood transfusions in a nonhematologic alloimmunized patient cohort: Is it time to take precautionary measures? Transfusion 2006;46:630-5.

21. Santos FW, Magalhães SM, Mota RM, Pitombeira MH. Additional red blood cell alloantibodies after blood transfusions in a nonhematologic alloimmunized patient cohort: Is it time to take precautionary measures? Transfusion 2006;46:630-5.